Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · Adolescents/teenagers undergoing orthodontic treatment
Experimental chewing adjuncts (bite wafers or chewing gum) showed no clear difference in patient‐reported pain intensity or pain relief (VAS, NRS or… compared with no chewing gum, placebo, or control (no adjunct); GRADE not reported.
5 findings from 1 review
MD -1.39 [-3.24, 0.64]
1 study · 39 participants
GRADE not reported
MD -29.16 [-51.67, -6.65]
1 study · 39 participants
GRADE not reported
MD -15.17 [-32.44, 2.11]
2 studies · 96 participants
GRADE not reported
Show 2 more findings
MD -15.38 [-28.90, -1.86]
2 studies · 96 participants
Very low
Non‐pharmacological interventions for alleviating pain during orthodontic treatment 2016 · Cochrane All outcomes1 day · Bite wafer subgroup (median data, opposite direction)
Otasevic 2006 (84 participants) presented median values only and reported higher median pain in the bite wafer group than the group who avoided chewing at one day (P = 0.006); data not suitable for meta‐analysis.
1 study · 84 participants
GRADE not reported
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · Adolescents and adults undergoing orthodontic treatment
Vibratory stimulation (vibratory adjuncts) showed no clear difference in patient‐reported pain intensity or pain relief (VAS, NRS or… compared with no vibration or placebo vibration; GRADE not reported.
5 findings from 1 review
MD 1.28 [-3.16, 5.71]
3 studies · 154 participants
GRADE not reported
MD -0.52 [-9.41, 8.36]
2 studies · 115 participants
GRADE not reported
Lobre 2015 (high risk of bias): mean overall pain intensity 8.49 mm lower on the VAS during the second month (P = 0.04) and 6.26 mm lower during the fourth month (P = 0.03); no evidence of benefit at month one or month…
2 studies
GRADE not reported
Show 2 more findings
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · Adults undergoing orthodontic treatment
Brain wave music (BWM) showed no clear difference in patient‐reported pain intensity or pain relief (VAS, NRS or… compared with no special instructions (control); GRADE not reported.
3 findings from 1 review
MD -4.72 [-15.83, 6.39]
1 study · 24 participants
GRADE not reported
MD -26.65 [-39.06, -14.24]
1 study · 24 participants
Very low
MD -23.44 [-36.82, -10.06]
1 study · 24 participants
GRADE not reported
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dose/intensity and frequency of pain relief needed (analgesic/rescue medication use) · Adolescents and adults undergoing orthodontic treatment
Vibratory stimulation (vibratory adjuncts) led to lower dose/intensity and frequency of pain relief needed (analgesic/rescue… compared with no vibration or placebo vibration; GRADE not reported.
1 finding from 1 review
RR 0.63 [0.44, 0.92]
2 studies
GRADE not reported
Quality of life or patient satisfaction · Adolescents/teenagers undergoing orthodontic treatment
Experimental chewing adjuncts (bite wafers or chewing gum) led to lower quality of life or patient satisfaction compared with no chewing gum, placebo, or control (no adjunct); GRADE not reported.
1 finding from 1 review
Dose/intensity and frequency of pain relief needed (analgesic/rescue medication use) · Adolescents/teenagers undergoing orthodontic treatment
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dysphagia (grade >= 3, 0-4 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine showed no clear difference in dysphagia (grade >= 3, 0-4 scale) compared with no treatment/placebo; GRADE not reported.
1 finding from 1 review
Salivary flow rate (stimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Chinese medicine led to higher salivary flow rate (stimulated) compared with no treatment/placebo; GRADE not reported.
1 finding from 1 review
Quality of life (McMaster HNRQ, 1-7 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
It is very uncertain whether pilocarpine changes quality of life (McMaster HNRQ, 1-7 scale) compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Disease-free survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine showed no clear difference in disease-free survival compared with no treatment/placebo; GRADE not reported.
1 finding from 1 review
Side effects · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Quality of life · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine showed no clear difference in quality of life compared with no treatment/placebo; GRADE not reported.
1 finding from 1 review
Salivary flow rate (unstimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
It is very uncertain whether amifostine changes salivary flow rate (mg/5 min, unstimulated) compared with no treatment/placebo (very low certainty).
2 findings from 1 review
Progression‐free survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine showed no clear difference in progression-free survival compared with no treatment/placebo; GRADE not reported.
1 finding from 1 review
Survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Survival not reported.
0 studies
No studies found
Dysgeusia (grade >= 2, 0-4 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine led to lower dysgeusia (grade >= 2, 0-4 scale) compared with no treatment/placebo; GRADE not reported.
1 finding from 1 review